2024-10-25-深交所-香雪制药_2024年三季度报告_10页_398kb

Guangzhou Xiangxue Pharmaceutical Co., Ltd. (300147) Q3 2024 Report Summary

Key Financial Data

• Revenue declined by 17.05% to 437 million yuan.
• Net profit attributable to shareholders was -82.5 million yuan, down 3.12% year-over-year.
• Non-recurring net profit was -96.8 million yuan, down significantly.
• Operating cash flow was negative, reflecting reduced earnings.

Changes in Assets and Liabilities

• Assets decreased by 11.32% in owner equity compared to year-end.
• Liabilities remained high, with negative net profit impacting overall financial health.

Non-Recurring Items

• Non-recurring income and expenses included government grants (+3.12% in net), investment gains/dismisses, and other gains/losses.

Significant Events

• Company transferred 51% stake in Beijing Xiangxue Pharmaceutical for 23.87 million yuan; this reduced assets.
• TAEST16001 injection was added to breakthrough therapy list, indicating potential drug development progress.

Ownership and Shareholders

• Top shareholders include Guangzhou Kunlun Investment (22.59% stake, pledged and frozen shares) and other key entities.

Notes:

• The report is unaudited for the third quarter of 2024.
• Overall performance shows decline in revenue and profits.